By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Fresh data on Biotechnology are presented in a new report. According to news reporting out of Izola, Slovenia, by NewsRx editors, research stated, "Radiation induced transcriptional targeting is a gene therapy approach that takes advantage of the targeting abilities of radiotherapy by using radio inducible promoters to spatially and temporally limit the transgene expression. Cyclin dependent kinase inhibitor 1 (CDKN1A), also known as p21, is a crucial regulator of the cell cycle, mediating G1 phase arrest in response to a variety of stress stimuli, including DNA damaging agents like irradiation."
Our news journalists obtained a quote from the research from the University of Primorska, "The aim of the study was to evaluate the suitability of the p21 promoter for radiation induced transcriptional targeting with the objective to test the therapeutic effectiveness of the combined radio-gene therapy with p21 promoter driven therapeutic gene interleukin 12. To test the inducibility of the p21 promoter, three reporter gene experimental models with green fluorescent protein (GFP) under the control of p21 promoter were established by gene electrotransfer of plasmid DNA: stably transfected cells, stably transfected tumors, and transiently transfected muscles. Induction of reporter gene expression after irradiation was determined using a fluorescence microplate reader in vitro and by non-invasive fluorescence imaging using fluorescence stereomicroscope in vivo. The antitumor effect of the plasmid encoding the p21 promoter driven interleukin 12 after radio-gene therapy was determined by tumor growth delay assay and by quantification of intratumoral and serum levels of interleukin 12 protein and intratumoral concentrations of interleukin 12 mRNA. Using the reporter gene experimental models, p21 promoter was proven to be inducible with radiation, the induction was not dose dependent, and it could be re-induced. Furthermore radio-gene therapy with interleukin 12 under control of the p21 promoter had a good antitumor therapeutic effect with the statistically relevant tumor growth delay, which was comparable to that of the same therapy using a constitutive promoter. In this study p21 promoter was proven to be a suitable candidate for radiation induced transcriptional targeting."
According to the news editors, the research concluded: "As a proof of principle the therapeutic value was demonstrated with the radio-inducible interleukin 12 plasmid providing a synergistic antitumor effect to radiotherapy alone, which makes this approach feasible for the combined treatment with radiotherapy."
For more information on this research see: Evaluation of p21 promoter for interleukin 12 radiation induced transcriptional targeting in a mouse tumor model. Molecular Cancer, 2013;12():13-24. Molecular Cancer can be contacted at: Biomed Central Ltd, 236 Grays Inn Rd, Floor 6, London WC1X 8HL, England. (BioMed Central - www.biomedcentral.com/; Molecular Cancer - www.molecular-cancer.com)
Our news journalists report that additional information may be obtained by contacting U. Kamensek, Univ Primorska, Fac Hlth Sci, Izola, Slovenia. Additional authors for this research include G. Sersa and M. Cemazar (see also technology.html">Biotechnology).
Keywords for this news article include: Biotechnology, Pharmaceuticals, Izola, Europe, Slovenia, Cytokines, Gene Therapy, Interleukins, Radiotherapy, Bioengineering
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC